Literature DB >> 22762424

The Colour Test for drug susceptibility testing of Mycobacterium tuberculosis strains.

K Toit1, S Mitchell, Y Balabanova, C A Evans, T Kummik, V Nikolayevskyy, F Drobniewski.   

Abstract

SETTING: Tartu, Estonia.
OBJECTIVE: To assess the performance and feasibility of the introduction of the thin-layer agar MDR/XDR-TB Colour Test (Colour Test) as a non-commercial method of drug susceptibility testing (DST).
DESIGN: The Colour Test combines the thin-layer agar technique with a simple colour-coded quadrant format, selective medium to reduce contamination and colorimetric indication of bacterial growth to simplify interpretation. DST patterns for isoniazid (INH), rifampicin (RMP) and ciprofloxacin (CFX) were determined using the Colour Test for 201 archived Mycobacterium tuberculosis isolates. Susceptibilities were compared to blinded DST results obtained routinely using the BACTEC™ Mycobacteria Growth Indicator Tube™ (MGIT) 960 to assess performance characteristics.
RESULTS: In all, 98% of the isolates produced interpretable results. The average time to positivity was 13 days, and all results were interpretable. The Colour Test detected drug resistance with 98% sensitivity for INH, RMP and CFX and 99% for multidrug-resistant tuberculosis. Specificities were respectively 100% (95%CI 82-100), 88% (95%CI 69-97) and 91% (95%CI 83-96) and 90% (95%CI 74-98). Agreement between the Colour Test and BACTEC MGIT 960 were respectively 98%, 96%, 94% and 97%.
CONCLUSION: The Colour Test could be an economical, accurate and simple technique for testing tuberculosis strains for drug resistance. As it requires little specialist equipment, it may be particularly useful in resource-constrained settings with growing drug resistance rates.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22762424     DOI: 10.5588/ijtld.11.0609

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  8 in total

1.  Non-commercial phenotypic assays for the detection of Mycobacterium tuberculosis drug resistance: a systematic review.

Authors:  Irina Kontsevaya; Jim Werngren; Yen Holicka; Kadri Klaos; Anh Tran; Vladyslav Nikolayevskyy
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-10-30       Impact factor: 3.267

2.  Low-cost diagnostic test for susceptible and drug-resistant tuberculosis in rural Malawi.

Authors:  Annie Zhang; Enoch Jumbe; Robert Krysiak; Sabeen Sidiki; Holden V Kelley; Elly K Chemey; Chancy Kamba; Victor Mwapasa; Juan I García; Alison Norris; Xueliang J Pan; Carlton Evans; Shu-Hua Wang; Jesse J Kwiek; Jordi B Torrelles
Journal:  Afr J Lab Med       Date:  2018-06-04

3.  Active and passive case-finding in tuberculosis-affected households in Peru: a 10-year prospective cohort study.

Authors:  Matthew J Saunders; Marco A Tovar; Dami Collier; Matthew R Baldwin; Rosario Montoya; Teresa R Valencia; Robert H Gilman; Carlton A Evans
Journal:  Lancet Infect Dis       Date:  2019-03-22       Impact factor: 71.421

4.  Evaluation of the tuberculosis culture color plate test for rapid detection of drug susceptible and drug-resistant Mycobacterium tuberculosis in a resource-limited setting, Addis Ababa, Ethiopia.

Authors:  Biruk Mekonnen; Adane Mihret; Muluwork Getahun; Tsegaye Hailu; Sabeen Sidiki; Holden V Kelley; Julia M Scordo; W Garrett Hunt; Xueliang Pan; Joan-Miquel Balada-Llasat; Wondwossen Gebreyes; Carlton A Evans; Abraham Aseffa; Jordi B Torrelles; Shu-Hua Wang; Tamrat Abebe
Journal:  PLoS One       Date:  2019-05-28       Impact factor: 3.240

Review 5.  Rapid point of care diagnostic tests for viral and bacterial respiratory tract infections--needs, advances, and future prospects.

Authors:  Alimuddin Zumla; Jaffar A Al-Tawfiq; Virve I Enne; Mike Kidd; Christian Drosten; Judy Breuer; Marcel A Muller; David Hui; Markus Maeurer; Matthew Bates; Peter Mwaba; Rafaat Al-Hakeem; Gregory Gray; Philippe Gautret; Abdullah A Al-Rabeeah; Ziad A Memish; Vanya Gant
Journal:  Lancet Infect Dis       Date:  2014-09-01       Impact factor: 25.071

6.  Quality of life, tuberculosis and treatment outcome; a case-control and nested cohort study.

Authors:  Sumona Datta; Robert H Gilman; Rosario Montoya; Luz Quevedo Cruz; Teresa Valencia; Doug Huff; Matthew J Saunders; Carlton A Evans
Journal:  Eur Respir J       Date:  2020-08-06       Impact factor: 16.671

Review 7.  Tuberculosis Phenotypic and Genotypic Drug Susceptibility Testing and Immunodiagnostics: A Review.

Authors:  Kizil A Yusoof; Juan Ignacio García; Alyssa Schami; Andreu Garcia-Vilanova; Holden V Kelley; Shu-Hua Wang; Adrian Rendon; Blanca I Restrepo; Marcel Yotebieng; Jordi B Torrelles
Journal:  Front Immunol       Date:  2022-07-07       Impact factor: 8.786

Review 8.  Rapid diagnostics of tuberculosis and drug resistance in the industrialized world: clinical and public health benefits and barriers to implementation.

Authors:  Francis Drobniewski; Vladyslav Nikolayevskyy; Horst Maxeiner; Yanina Balabanova; Nicola Casali; Irina Kontsevaya; Olga Ignatyeva
Journal:  BMC Med       Date:  2013-08-29       Impact factor: 8.775

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.